Stock CPCI KAHIRA PHARMACEUTICALS & CHEMICAL INDUSTRIES COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Financials Kahira Pharmaceuticals & Chemical Industries Company

Equities

CPCI

EGS38391C016

Pharmaceuticals

End-of-day quote Egyptian Exchange
Other stock markets
 06:00:00 2024-07-09 pm EDT 		5-day change 1st Jan Change
69.86 EGP -1.01% Intraday chart for Kahira Pharmaceuticals & Chemical Industries Company +2.09% +23.54%
May. 27 Kahira Pharmaceuticals & Chemical Industries Company Reports Earnings Results for the Nine Months Ended March 31, 2024 CI
2023 Kahira Pharmaceuticals & Chemical Industries Company Reports Earnings Results for the First Quarter Ended September 30, 2023 CI

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 536.9 466 430.2 538.5 551.4 636.7
Enterprise Value (EV) 1 442.9 315.1 347.9 396.7 497.9 665.3
P/E ratio 4.95 x 5.47 x 3.94 x 4.33 x 3.33 x 6.56 x
Yield - - 9.3% 11.1% 13.5% 11.7%
Capitalization / Revenue 0.62 x 0.48 x 0.43 x 0.51 x 0.5 x 0.63 x
EV / Revenue 0.51 x 0.33 x 0.34 x 0.37 x 0.45 x 0.66 x
EV / EBITDA 3.07 x 2.72 x 2.24 x 2.5 x 2.4 x 7.53 x
EV / FCF 743 x 3.18 x -9.43 x 4.22 x -99.6 x 9.32 x
FCF Yield 0.13% 31.4% -10.6% 23.7% -1% 10.7%
Price to Book 0.93 x 0.77 x 0.66 x 0.77 x 0.69 x 0.93 x
Nbr of stocks (in thousands) 14,934 14,934 14,934 14,934 14,934 14,934
Reference price 2 35.95 31.20 28.81 36.06 36.92 42.63
Announcement Date 8/29/18 8/29/19 8/30/20 9/8/21 9/21/22 10/9/23
1EGP in Million2EGP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 862.9 962.9 1,010 1,062 1,112 1,005
EBITDA 1 144.3 115.8 155.3 158.7 207.3 88.3
EBIT 1 132.7 105.2 142.9 158.2 192.1 76.74
Operating Margin 15.38% 10.92% 14.14% 14.9% 17.27% 7.63%
Earnings before Tax (EBT) 1 144.6 109.2 141.4 163.1 214.1 127.6
Net income 1 108.5 85.17 109.1 124.3 165.7 97.09
Net margin 12.57% 8.84% 10.8% 11.7% 14.9% 9.66%
EPS 2 7.262 5.703 7.308 8.323 11.10 6.501
Free Cash Flow 1 0.5964 99.07 -36.88 94.06 -4.998 71.41
FCF margin 0.07% 10.29% -3.65% 8.86% -0.45% 7.1%
FCF Conversion (EBITDA) 0.41% 85.52% - 59.28% - 80.87%
FCF Conversion (Net income) 0.55% 116.32% - 75.67% - 73.55%
Dividend per Share - - 2.680 4.000 5.000 5.000
Announcement Date 8/29/18 8/29/19 8/30/20 9/8/21 9/21/22 10/9/23
1EGP in Million2EGP
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - 28.6
Net Cash position 1 94 151 82.4 142 53.5 -
Leverage (Debt/EBITDA) - - - - - 0.3241 x
Free Cash Flow 1 0.6 99.1 -36.9 94.1 -5 71.4
ROE (net income / shareholders' equity) 20.5% 14.4% 17.4% 18.3% 22.1% 13.1%
ROA (Net income/ Total Assets) 9.38% 6.7% 8.74% 9.62% 10.7% 3.95%
Assets 1 1,156 1,271 1,249 1,293 1,544 2,460
Book Value Per Share 2 38.90 40.40 43.80 47.10 53.20 46.00
Cash Flow per Share 2 6.300 10.10 5.520 8.820 7.490 9.330
Capex 1 45.6 11.5 8.34 23.7 17.3 79.1
Capex / Sales 5.29% 1.19% 0.83% 2.23% 1.56% 7.87%
Announcement Date 8/29/18 8/29/19 8/30/20 9/8/21 9/21/22 10/9/23
1EGP in Million2EGP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
KAHIRA PHARMACEUTICALS & CHEMICAL INDUSTRIES COMPANY Stock Kahira Pharmaceuticals & Chemical Industries Company
+23.54% 21.74M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+61.22% 846B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.18% 628B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.66% 360B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.77% 322B
ABBVIE INC. Stock AbbVie Inc.
+8.50% 297B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.13% 240B
NOVARTIS AG Stock Novartis AG
+17.85% 223B
ROCHE HOLDING AG Stock Roche Holding AG
+2.74% 224B
AMGEN INC. Stock Amgen Inc.
+11.68% 173B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CPCI Stock
  4. Financials Kahira Pharmaceuticals & Chemical Industries Company